Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

This study has been completed.
Information provided by (Responsible Party):
Tae Won Kim, Asan Medical Center Identifier:
First received: March 10, 2008
Last updated: July 17, 2014
Last verified: July 2014

The purpose of this study is to investigate the response rate of cetuximab plus irinotecan every 2 weeks in patients harboring wild-type KRAS with and without detectable EGFR-expressing metastatic CRC after failure to irinotecan in an exploratory manner.

Condition Intervention Phase
Advanced Colorectal Cancer
Drug: Cetuximab, irinotecan
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Cetuximab Plus Irinotecan as a 2nd-line Treatment in Patients With Metastatic Colorectal Cancer After Failure to Irinotecan That Express Wild-type KRAS With and Without Detectable EGFR Expression

Resource links provided by NLM:

Further study details as provided by Asan Medical Center:

Primary Outcome Measures:
  • Response rate [ Time Frame: 8 week ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Progression free survival, overall survival [ Time Frame: every 8 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: March 2008
Study Completion Date: September 2011
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EGFR expression
Patients' accrual will be adjusted by EGFR expression (positive vs. negative)
Drug: Cetuximab, irinotecan
cetuximab, irinotecan
Other Name: PharmDx kit for EGFR staining.

Detailed Description:

Twenty patients with positive-EGFR results and 20 patients with negative-EGFR results will be accrued in this study. All patients should have wild-type KRAS.


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Colorectal adenocarcinoma, Wild KRAS, 18-75 yr
  • Estimated life expectancy of more than 3 months
  • ECOG performance status of 0 to 1 at study entry
  • Adequate bone marrow function
  • Adequate liver function
  • Documented progression during or within 3 months of irinotecan-containing regimens as a first-line chemotherapy
  • Immunohistochemical evidence of a presence or absence of EGFR expression by PharmDx Kit
  • Informed Consent

Exclusion Criteria:

  • Central nervous system (CNS) metastases or prior radiation for CNS metastases.
  • Intestinal obstruction or impending intestinal obstruction due to peritoneal carcinomatosis
  • Surgery (excluding biopsy for diagnosis) during 4 weeks prior to inclusion in the study.
  • Evidence of gastrointestinal bleeding
  • Exposure to Cetuximab
  • Prior administration of monoclonal antibodies, EGFR signal transduction inhibitors or EGFR-targeted treatment
  • KRAS mutant Status
  • Patients with serious toxicity to previous irinotecan-based chemotherapy
  • Other serious illness or medical conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00637091

Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of, 138736
Sponsors and Collaborators
Asan Medical Center
  More Information

Responsible Party: Tae Won Kim, Professor, Asan Medical Center Identifier: NCT00637091     History of Changes
Other Study ID Numbers: AMC-ONCGI-2008-0031
Study First Received: March 10, 2008
Last Updated: July 17, 2014
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors processed this record on November 24, 2014